A Phase 1b/2, Open-label, Dose Escalation Study of Entinostat in Combination With Pembrolizumab in Patients With Non-small Cell Lung Cancer, With Expansion Cohorts in Patients With Non-small Cell Lung Cancer and Melanoma

What is the purpose of this trial?

The purpose of this study is to determine the safety and tolerability of entinostat used in combination with pembrolizumab in patients with Non-small Cell Lung Cancer. Additionally the purpose of the study is to assess how effective entinostat and pembrolizumab are in combination in patients with Non-small Cell Lung Cancer and Melanoma.



Syndax Corporation

Start Date: 02/15/2017

End Date: 08/01/2019

Last Updated: 07/01/2018

Study HIC#: 1509016482

Get Involved

For more information about this study, contact:
Kira Fitzsimons Pavlik
+1 203-785-6540
kira.pavlik@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image